Hepatitis C Virus Infection in the Older Patient

Infectious Disease Clinics of North America

Volumn 31, Issue 4, 2017, Pages 827-838

  Reid, Michael ^a   Price, Jennifer C ^a   Tien, Phyllis C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aging; Comorbidity; HCV; Inflammation

Indexed keywords

ANTIVIRUS AGENT;

AGE; AGED; AGING; CARDIOVASCULAR DISEASE; CLINICAL OUTCOME; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISORDERS OF HIGHER CEREBRAL FUNCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY DISEASE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALIGNANT NEOPLASM; MENTAL DISEASE; REVIEW; UNITED STATES; COMPLICATION; HEPACIVIRUS; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

AGED; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED;

EID: 85032292417     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2017.07.014     Document Type: Review

References (65)

1. Armstrong, G.L., Wasley, A., Simard, E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:10 (2006), 705–714.
2. Rein, D.B., Smith, B.D., Wittenborn, J.S., et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 156:4 (2012), 263–270.
3. Suryaprasad, A.G., White, J.Z., Xu, F., et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 59:10 (2014), 1411–1419.
4. Smith, B.D., Morgan, R.L., Beckett, G.A., et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 61:RR-4 (2012), 1–32.
5. Smith, B.D., Beckett, G.A., Yartel, A., et al. Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008. Am J Public Health 104:3 (2014), 474–481.
6. Alvarez, K.J., Smaldone, A., Larson, E.L., Burden of hepatitis C virus infection among older adults in long-term care settings: a systematic review of the literature and meta-analysis. Curr Infect Dis Rep, 18(4), 2016, 13.
7. Perz, J.F., Grytdal, S., Beck, S., et al. Case-control study of hepatitis B and hepatitis C in older adults: do healthcare exposures contribute to burden of new infections?. Hepatology 57:3 (2013), 917–924.
8. Wasley, A., Alter, M.J., Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20:1 (2000), 1–16.
9. Denniston, M.M., Jiles, R.B., Drobeniuc, J., et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 160:5 (2014), 293–300.
10. Alter, H.J., Seeff, L.B., Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 20:1 (2000), 17–35.
11. Davis, G.L., Albright, J.E., Cook, S.F., et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9:4 (2003), 331–338.
12. Pessoa, M.G., Wright, T.L., Hepatitis C infection in transplantation. Clin Liver Dis 1:3 (1997), 663–690.
13. El-Serag, H.B., Kramer, J., Duan, Z., et al. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat 23:9 (2016), 687–696.
14. Pradat, P., Voirin, N., Tillmann, H.L., et al. Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int 27:3 (2007), 335–339.
15. Tong, M.J., el-Farra, N.S., Reikes, A.R., et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332:22 (1995), 1463–1466.
16. Minola, E., Prati, D., Suter, F., et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 99:12 (2002), 4588–4591.
17. Lake, J.R., Shorr, J.S., Steffen, B.J., et al. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 5:3 (2005), 549–557.
18. Poynard, T., Ratziu, V., Charlotte, F., et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 34:5 (2001), 730–739.
19. Horiike, N., Masumoto, T., Nakanishi, K., et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 10:3 (1995), 246–249.
20. Barathan, M., Mohamed, R., Saeidi, A., et al. Increased frequency of late-senescent T cells lacking CD127 in chronic hepatitis C disease. Eur J Clin Invest 45:5 (2015), 466–474.
21. Chou, J.P., Effros, R.B., T cell replicative senescence in human aging. Curr Pharm Des 19:9 (2013), 1680–1698.
22. Mahale, P., Torres, H.A., Kramer, J.R., et al. Hepatitis C virus infection and the risk of cancer among elderly US adults: a registry-based case-control study. Cancer 123:7 (2017), 1202–1211.
23. Zignego, A.L., Macchia, D., Monti, M., et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol 15:3 (1992), 382–386.
24. Zignego, A.L., Giannini, C., Gragnani, L., HCV and lymphoproliferation. Clin Dev Immunol, 2012, 2012, 980942.
25. Molnar, M.Z., Alhourani, H.M., Wall, B.M., et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology 61:5 (2015), 1495–1502.
26. Park, H., Adeyemi, A., Henry, L., et al. A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat 22:11 (2015), 897–905.
27. Perico, N., Cattaneo, D., Bikbov, B., et al. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 4:1 (2009), 207–220.
28. Chen, Y.C., Lin, H.Y., Li, C.Y., et al. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int 85:5 (2014), 1200–1207.
29. Fischer, M.J., Wyatt, C.M., Gordon, K., et al. Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr 53:2 (2010), 222–226.
30. Buettner, M., Toennes, S.W., Buettner, S., et al. Nephropathy in illicit drug abusers: a postmortem analysis. Am J Kidney Dis 63:6 (2014), 945–953.
31. Abraham, A.G., Althoff, K.N., Jing, Y., et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis 60:6 (2015), 941–949.
32. Stepanova, M., Lam, B., Younossi, Y., et al. Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. J Viral Hepat 19:5 (2012), 341–345.
33. Mangia, A., Ripoli, M., Insulin resistance, steatosis and hepatitis C virus. Hepatol Int 7:Suppl 2 (2013), 782–789.
34. Younossi, Z.M., Stepanova, M., Nader, F., et al. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther 37:6 (2013), 647–652.
35. Mehta, S.H., Brancati, F.L., Sulkowski, M.S., et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology, 33(6), 2001, 1554.
36. Mehta, S.H., Brancati, F.L., Strathdee, S.A., et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 38:1 (2003), 50–56.
37. Mehta, S.H., Strathdee, S.A., Thomas, D.L., Association between hepatitis C virus infection and diabetes mellitus. Epidemiol Rev 23:2 (2001), 302–312.
38. Kawaguchi, Y., Mizuta, T., Interaction between hepatitis C virus and metabolic factors. World J Gastroenterol 20:11 (2014), 2888–2901.
39. Aytug, S., Reich, D., Sapiro, L.E., et al. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 38:6 (2003), 1384–1392.
40. Kawaguchi, T., Yoshida, T., Harada, M., et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165:5 (2004), 1499–1508.
41. Kawaguchi, T., Ide, T., Taniguchi, E., et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 102:3 (2007), 570–576.
42. Fibach, E., Gatt, S., Rachmilewitz, E.A., Selective photosensitization of human leukemic cells by a pyrene-containing fatty acid. Exp Hematol 18:2 (1990), 89–93.
43. Oliveira, C.P., Kappel, C.R., Siqueira, E.R., et al. Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol 164:2 (2013), 221–226.
44. Boddi, M., Abbate, R., Chellini, B., et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol 47:1 (2010), 72–75.
45. Fabris, C., Federico, E., Soardo, G., et al. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta 261:2 (1997), 159–165.
46. Khovidhunkit, W., Kim, M.S., Memon, R.A., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45:7 (2004), 1169–1196.
47. Siagris, D., Christofidou, M., Theocharis, G.J., et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 13:1 (2006), 56–61.
48. Hassoun, Z., Willems, B., Deslauriers, J., et al. Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci 47:12 (2002), 2674–2681.
49. Forton, D.M., Altered monoaminergic transporter binding in hepatitis C related cerebral dysfunction: a neuroimmunologial condition?. Gut 55:11 (2006), 1535–1537.
50. Casato, M., Saadoun, D., Marchetti, A., et al. Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis: a multicenter case-control study using magnetic resonance imaging and neuropsychological tests. J Rheumatol 32:3 (2005), 484–488.
51. Weissenborn, K., Ennen, J.C., Bokemeyer, M., et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 55:11 (2006), 1624–1630.
52. Perry, W., Hilsabeck, R.C., Hassanein, T.I., Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci 53:2 (2008), 307–321.
53. Kramer, L., Bauer, E., Funk, G., et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 37:3 (2002), 349–354.
54. Fontana, R.J., Bieliauskas, L.A., Back-Madruga, C., et al. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol 43:4 (2005), 614–622.
55. Laskus, T., Radkowski, M., Bednarska, A., et al. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol 76:19 (2002), 10064–10068.
56. Paulino, A.D., Ubhi, K., Rockenstein, E., et al. Neurotoxic effects of the HCV core protein are mediated by sustained activation of ERK via TLR2 signaling. J Neurovirol 17:4 (2011), 327–340.
57. Letendre, S., Paulino, A.D., Rockenstein, E., et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 196:3 (2007), 361–370.
58. Sato, I., Shimbo, T., Kawasaki, Y., et al. Efficacy and safety of interferon treatment in elderly patients with chronic hepatitis C in Japan: a retrospective study using the Japanese Interferon Database. Hepatol Res 45:8 (2015), 829–836.
59. Tsui, J.I., Currie, S., Shen, H., et al. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci 53:3 (2008), 809–814.
60. Ioannou, G.N., Beste, L.A., Chang, M.F., et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology 151:3 (2016), 457–471.e5.
61. Saab, S., Park, S.H., Mizokami, M., et al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology 63:4 (2016), 1112–1119.
62. Su, F., Beste, L.A., Green, P.K., et al. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients. Eur J Gastroenterol Hepatol 29:6 (2017), 686–693.
63. El-Serag, H.B., Kanwal, F., Richardson, P., et al. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 64:1 (2016), 130–137.
64. Mastrorosa, I., Lorenzini, P., Ricottini, M., et al. DAAs improve VACS but do not influence cognitive impairment in HIV/HCV coinfected. 2017, CROI, Seattle (WA).
65. Thein, H.H., Maruff, P., Krahn, M.D., et al. Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med 8:8 (2007), 520–528.